Adjuvant chemotherapy in older women with early-stage breast cancer

Hyman B. Muss, Donald A. Berry, Constance T. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, Heather P. Becker, Patricia A. Kartcheske, Judith D. Wheeler, Edith A. Perez, Antonio C. Wolff, Julie R. Gralow, Harold J. Burstein, Ahmad A. Mahmood, Gutav Magrinat, Barbara A. Parker, Ronald D. HartDebjani Grenier, Larry Norton, Clifford A. Hudis, Eric P. Winer

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older. METHODS: We randomly assigned patients with stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin) or capecitabine. Endocrine therapy was recommended after chemotherapy in patients with hormone-receptor-positive tumors. A Bayesian statistical design was used with a range in sample size from 600 to 1800 patients. The primary end point was relapse-free survival. RESULTS: When the 600th patient was enrolled, the probability that, with longer follow-up, capecitabine therapy was highly likely to be inferior to standard chemotherapy met a prescribed level, and enrollment was discontinued. After an additional year of follow-up, the hazard ratio for disease recurrence or death in the capecitabine group was 2.09 (95% confidence interval, 1.38 to 3.17; P<0.001). Patients who were randomly assigned to capecitabine were twice as likely to have a relapse and almost twice as likely to die as patients who were randomly assigned to standard chemotherapy (P=0.02). At 3 years, the rate of relapse-free survival was 68% in the capecitabine group versus 85% in the standard-chemotherapy group, and the overall survival rate was 86% versus 91%. Two patients in the capecitabine group died of treatment-related complications; as compared with patients receiving capecitabine, twice as many patients receiving standard chemotherapy had moderate-to-severe toxic effects (64% vs. 33%). CONCLUSIONS: Standard adjuvant chemotherapy is superior to capecitabine in patients with earlystage breast cancer who are 65 years of age or older. (ClinicalTrials.gov number, NCT00024102.)

Original languageEnglish (US)
Pages (from-to)2055-2065
Number of pages11
JournalNew England Journal of Medicine
Volume360
Issue number20
DOIs
StatePublished - May 14 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adjuvant chemotherapy in older women with early-stage breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., Dressler, L. G., Cohen, H. J., Becker, H. P., Kartcheske, P. A., Wheeler, J. D., Perez, E. A., Wolff, A. C., Gralow, J. R., Burstein, H. J., Mahmood, A. A., Magrinat, G., Parker, B. A., ... Winer, E. P. (2009). Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine, 360(20), 2055-2065. https://doi.org/10.1056/NEJMoa0810266